AnaptysBio Inc., a clinical-stage biotechnology company, is involved in ongoing litigation with Tesaro, a GSK subsidiary, regarding their Collaboration and Exclusive License Agreement related to royalties from sales of Jemperli. The dispute centers on claims of breach of contract and anticipatory breach. Tesaro initiated a lawsuit alleging AnaptysBio had repudiated the agreement, while AnaptysBio countered with its own complaint asserting Tesaro and GSK had materially breached the contract and that GSK had tortiously interfered. On December 30, 2025, AnaptysBio filed a motion to dismiss Tesaro's anticipatory breach claim, arguing that its legal actions do not constitute repudiation and invoking Delaware's anti-SLAPP law to prevent strategic litigation aimed at deterring good-faith contract enforcement. A trial to resolve all claims is scheduled for July 14-17, 2026, with a decision on the motion to dismiss expected by early March.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AnaptysBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9622645-en) on January 08, 2026, and is solely responsible for the information contained therein.